Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

Definium Therapeutics: 3 Key Takeaways for Long-Term Investors

Two encouraging changes from five patients hint at a pipeline beyond depression and anxiety, but the early-stage data leaves open whether DT402 can carry that weight.

We haven't written up this one. Motley Fool has the full story — the link below goes straight to it.

Also reported by 1 other outlet

Every outlet that reported this, and when →

Read the original at fool.com →

More in Finance & Markets

More from Monday 16 November →